One lot of a nationally distributed diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine was recalled in January 1999 because of a subpotent diphtheria toxoid component. To evaluate vaccine immunogenicity, children who had received the recalled lot for at least 2 of the 3 doses of their primary series were identified. Diphtheria antitoxin (DAT) levels were then prospectively assessed before and after dose 4 of (fully potent) DTaP vaccine. Of the 105 children evaluated, 84% had prevaccination DAT levels !0.10 IU/mL, which is the level generally accepted as protective. DAT levels rose a mean of 92-fold after dose 4; 100% of subjects had DAT levels у0.10 IU/mL, and 69% had DAT levels у1.0 IU/mL. These results indicate that diphtheria potency testing can identify vaccine that is less immunogenic when administered during the primary series. The booster response to dose 4, although reduced, was sufficient to confer adequate protection in the interval before receipt of the fifth dose of DTaP.
In January 1999, Pasteur Mérieux Connaught (now Aventis Pasteur) voluntarily recalled lot 0916490 of nationally distributed Tripedia diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine. Testing before release of the vaccine in February 1998 showed that the vaccine was up to standard, but routine postrelease stability testing revealed that the potency of the diphtheria toxoid component of this lot had fallen below specification. Potency was estimated to be 1.7-1.8 U (below the minimum acceptable limit of 2.0 U). The potencies of the tetanus and pertussis components were satisfactory.
Subsequently, the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics, and the American Academy of Family Practice issued a joint set of recommendations for children who had received the recalled lot [1] . Supplemental DTaP vaccination was recommended only for children who had completed the primary DTaP series but had not yet received dose 4, who had received the recalled lot for at least 2 of the 3 doses of the primary series, and who would be traveling to countries considered to carry high risk for exposure to diphtheria before they received their fourth dose of DTaP. Since diphtheria is rare in the United States [2] , children who had received the recalled lot during their primary series but who had not yet received the fourth dose of DTaP would be at very low risk of disease before they received dose 4, even if they lacked protective levels of immunity to diphtheria.
These recommendations were based in part on 2 assumptions regarding children who had received у2 doses of the recalled lot during the primary series: First, these children might not have protective levels of diphtheria antitoxin (DAT) after the primary series, and, second, they would still respond adequately to a fourth dose of fully potent vaccine and thus would have an acceptable level and duration of protection after dose 4. To obtain additional data relevant to these assumptions, we identified children who had received the recalled lot for у2 doses of the primary series and prospectively assessed DAT levels before and after the fourth dose of fully potent DTaP vaccine given at age 15 months.
Methods
Participants were children enrolled in the Group Health Cooperative (GHC), a health maintenance organization in Washington State that has an annual birth cohort of ∼3500 children. GHC has a computerized immunization tracking system in which information on vaccines administered to its members, including the type of vaccine, date of administration, manufacturer, and lot number, is recorded. Since January 1997, GHC has participated in a postmarketing surveillance assessment of Tripedia DTaP vaccine; there- fore, this vaccine has been the DTaP vaccine routinely used at GHC. Between February 1998 and the recall in January 1999, ∼4700 doses of the recalled lot of DTaP had been administered to children at GHC. For this study, GHC systems were used to identify children !2 years old who had been enrolled at GHC since birth, who had completed the primary DTaP series but had not yet received dose 4 of DTaP, and who had received the recalled lot for at least 2 of the 3 doses in the primary series. Blood specimens were obtained before and 1 month after the fourth dose of (fully potent) Tripedia DTaP, administered per routine practice at ∼15 months of age. Other vaccines were administered at the same visit at the discretion of the health care provider.
Serum antibody titers against diphtheria toxin were determined by the Vero cell toxin neutralization test, a functional test that measures the ability of the test sera to protect Vero cells from a diphtheria toxin challenge. By use of sterile 96-well microtiter plates, 2-fold dilutions of test sera, beginning with a 1:4 dilution, were challenged with diphtheria toxin and allowed to incubate. Vero cells were added, and wells were sealed with sterile mineral oil and incubated for 6-8 days. Antibody levels then were determined by observing a color change of the pH indicator in the media that resulted from the byproducts of cell metabolism. Results are reported as international units per milliliter, after standardization with reference sera provided by the World Health Organization.
Results
We identified 320 children who met the eligibility criteria. Of those, 59 had received dose 4 of DTaP by the time they were contacted by study staff. Of the rest, consent for participation was obtained for 183 children, and, of those, pre-and postvaccination specimens were collected from 105. For these subjects, prevaccination specimens were collected between 29 March and 30 September 1999; postvaccination specimens were collected between 7 May and 3 November 1999.
Of the 105 subjects, 71% percent were white, 12% Asian, and 5% black. No information on race was available for the others. Boys made up 55% of the study group. The mean age at administration of dose 4 was 15.3 months (range, 14.5-18.4 months), and the mean number of months between doses 3 and 4 of DTaP was 8.9 (range, 7.4-12.2 months). A total of 213 doses of the recalled lot had been administered to the 105 study subjects between March 1998 and January 1999; 77% of these doses were administered between May and August 1998. Table 1 shows the DAT levels before and after the booster dose of fully potent DTaP vaccine. DAT levels rose substantially after dose 4, with a mean 92-fold increase. Postvaccination DAT levels varied depending on the prevaccination DAT level. Among children with prevaccination DAT levels р0.01 IU/mL, the postvaccination geometric mean concentration (GMC) was 0.59 IU/mL (95% confidence interval [CI], 0.44-0.80 IU/mL); among those with prevaccination DAT levels 10.01 and р0.10 IU/mL, the postvaccination GMC was 1.65 IU/mL (95% CI, 1.32-2.06 IU/mL); and among those with prevaccination DAT levels 10.10 IU/mL, the postvaccination GMC was 2.89 IU/ mL (95% CI, 2.11-3.96 IU/mL). All subjects with prevaccination DAT levels р0.01 IU/mL had a у32-fold increase in DAT level after vaccination, and all had postvaccination DAT levels у0.16 IU/mL. However, only 36% (11/31) of this group had a postvaccination DAT level у1.0 IU/mL, compared with 82% (61/74) of subjects with prevaccination DAT levels 10.01 IU/ mL ( ). P ! .001 There was no difference in pre-or postvaccination DAT GMC among children who had received the recalled lot for doses 1 and 2 of the primary series, compared with those who had received the recalled lot for doses 2 and 3. Pre-and postvaccination DAT GMCs also did not vary significantly by age at receipt of dose 4, interval between doses 3 and 4, or month that the subject received the first dose of the recalled lot (data not shown).
Discussion
These results support the recommendations issued in response to the recall. Among the children in our study, 84% had DAT levels !0.1 IU/mL, the level generally accepted as consistently protective [3, 4] , before receipt of dose 4. Therefore, the recommendations for supplemental vaccination for children primed with у2 doses of the recalled lot who would be travelling to areas with high exposure to diphtheria before receipt of dose 4 were warranted.
After the booster dose of fully potent DTaP vaccine, 69% of subjects had DAT levels у1.0 IU/mL. DAT levels у1.0 IU/mL generally are accepted as indicative of more durable protection that lasts several years [3, 4] . Children with prevaccination DAT levels р0.01 IU/mL were less likely to achieve postvaccination DAT levels у1.0 IU/mL; however, all these children had postvaccination DAT levels у0.10 IU/mL and should be protected in the interval before dose 5. These results suggest that supplemental vaccination was not required for children who had received the fourth dose of DTaP, regardless of whether they had received the recalled lot during the primary series, and that they could complete the 5-dose series on the standard schedule.
We were able to conduct this assessment in response to the vaccine recall because GHC maintains an immunization da-tabase that records information, including vaccine type and lot number, on vaccines administered to its members. This information can be used to identify potentially eligible participants for prospective assessments, such as this one, or to link with other databases that record information on clinical outcomes for retrospective epidemiologic studies. Currently, 6 managed care organizations, including GHC, collaborate with the CDC in the Vaccine Safety Datalink (VSD) project [5, 6] . The VSD project has utilized the combined database capacities of the participating organizations to conduct both prospective [7] and retrospective [8, 9] evaluations of the safety of licensed vaccines, further demonstrating the value of these managed care-based systems for population-based evaluations of the safety of vaccines in routine use.
One limitation of our study is that we did not evaluate the DAT response to dose 4 among a comparable group of children who had received fully potent Tripedia vaccine for all doses of the primary series. However, comparison with the results of previous assessments of the vaccine suggests that our DAT levels before and after dose 4 were lower than would be expected for children primed with fully potent vaccine. In one study of 88 children who had received dose 4 of Tripedia vaccine after having been primed with the same vaccine, mean pre-and postvaccination DAT levels were 1.2 and 6.8 IU/mL (95% CIs not provided) [10] . In a more recent assessment of the immunogenicity of dose 4 of DTaP, pre-and postvaccination DAT GMCs for 10 subjects who had received Tripedia for all 4 doses were 2.5 IU/mL (95% CI, 1.1-5.6 IU/mL) and 5.1 IU/mL (95% CI, 3.0-8.5 IU/mL) [11] . In an assessment of 160 children who had received a whole-cell diphtheria and tetanus toxoids and pertussis vaccine for the primary series and Tripedia for dose 4 at age 18 months, pre-and postvaccination DAT GMCs for dose 4 were 0.32 IU/mL and 14.72 IU/mL, respectively [12] . Our mean pre-and postimmunization DAT levels of 0.027 and 1.34 IU/mL suggest that receipt of the recalled lot for 2 doses of the primary series was associated with a substantially diminished DAT response to the primary series and with a reduced response to dose 4. This indicates a concordance between the results of the potency testing and the immunogenicity of the diphtheria toxoid component of the recalled lot of vaccine.
Other limitations of our study include that we assessed only the response to a booster dose of Tripedia. Thus, we cannot generalize these findings to children primed with the recalled lot who then received another DTaP vaccine for the booster dose. In addition, the kinetics of the decline in diphtheria potency of the recalled lot are not known; therefore, it is possible that response to the diphtheria toxoid component of the vaccine may have varied depending on when the vaccine was administered. Since most of the doses (77%) of the recalled lot administered to children in our study were given over a fairly short interval (from May through August 1998), our ability to assess variation in immunogenicity by date of administration was limited.
In summary, the results of this assessment indicate that diphtheria potency testing can identify vaccine that is less immunogenic when administered during the primary series. If such a vaccine has been distributed, measures to ensure that recipients are not at increased risk of disease are warranted. Children who have received vaccine during the primary series that is subpotent but that has some potency remaining can have an acceptable DAT response to dose 4.
